Mitochondrial injury and dysfunction in hypertension-induced cardiac damage

European Heart Journal

Volumn 35, Issue 46, 2014, Pages 3258-3266

  Eirin, Alfonso ^a   Lerman, Amir ^a   Lerman, Lilach O ^a  

^a MAYO CLINIC   (United States)

Author keywords

Blood pressure; Hypertension; Mitochondria

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; CALCIUM; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MESSENGER RNA; MITOCHONDRIAL DNA; MITOFUSIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; VALSARTAN;

BIOENERGY; CALCIUM CELL LEVEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOTHELIAL DYSFUNCTION; ENERGY YIELD; ESSENTIAL HYPERTENSION; HEART INJURY; HEART MITOCHONDRION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LIPID PEROXIDATION; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REVIEW; ANIMAL; COMPLICATION; DISEASE MODEL; HEART DISEASES; HOMEOSTASIS; METABOLISM; MITOCHONDRIAL DISEASES; MOUSE; PHYSIOLOGY; PIG; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DISEASE MODELS, ANIMAL; HEART DISEASES; HOMEOSTASIS; HUMANS; HYPERTENSION; MICE; MITOCHONDRIA, HEART; MITOCHONDRIAL DISEASES; RATS; REACTIVE OXYGEN SPECIES; SWINE;

EID: 84926152755     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu436     Document Type: Review

References (86)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223.
2. McFarland R, Taylor RW, Turnbull DM. Mitochondrial disease-its impact, etiology, and pathology. Curr Top Dev Biol 2007; 77: 113-155.
3. Duchen MR. Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol Aspects Med 2004; 25: 365-451.
4. Ritz P, Berrut G. Mitochondrial function, energy expenditure, aging and insulin resistance. Diabetes Metab 2005; 31(Spec No 2): 5S67-65S73.
5. Cogliati S, Frezza C, Soriano ME, Varanita T, Quintana-Cabrera R, Corrado M, Cipolat S, Costa V, Casarin A, Gomes LC, Perales-Clemente E, Salviati L, Fernandez-Silva P, Enriquez JA, Scorrano L. Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency. Cell 2013; 155: 160-171.
6. Frey TG, Mannella CA. The internal structure of mitochondria. Trends Biochem Sci 2000; 25: 319-324.
7. Osman C, Voelker DR, Langer T. Making heads or tails of phospholipids in mitochondria. J Cell Biol 2011; 192: 7-16.
8. Finsterer J. Mitochondriopathies. Eur J Neurol 2004; 11: 163-186.
9. Paradies G, Petrosillo G, Pistolese M, Ruggiero FM. Reactive oxygen species affect mitochondrial electron transport complex I activity through oxidative cardiolipin damage. Gene 2002; 286: 135-141.
10. Paradies G, Petrosillo G, Pistolese M, Ruggiero FM. Reactive oxygen species generated by the mitochondrial respiratory chain affect the complex III activity via cardiolipin peroxidation in beef-heart submitochondrial particles. Mitochondrion 2001; 1: 151-159.
11. Okado-Matsumoto A, Fridovich I. Subcellular distribution of superoxide dismutases (sod) in rat liver: Cu, Zn-SOD in mitochondria. J Biol Chem 2001; 276: 38388-38393.
12. Weinberg JM. Mitochondrial biogenesis in kidney disease. J Am Soc Nephrol 2011; 22: 431-436.
13. Zhu J, Wang KZ, Chu CT. After the banquet: mitochondrial biogenesis, mitophagy, and cell survival. Autophagy 2013; 9: 1663-1676.
14. Zhan M, Brooks C, Liu F, Sun L, Dong Z. Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology. Kidney Int 2013; 83: 568-581.
15. Archer SL. Mitochondrial dynamics-mitochondrial fission and fusion in human diseases. N Engl J Med 2013; 369: 2236-2251.
16. Dengjel J, Abeliovich H. Musical chairs during mitophagy. Autophagy 2014; 10: 706-707.
17. Hickey AJ, Chai CC, Choong SY, de Freitas Costa S, Skea GL, Phillips AR, Cooper GJ. Impaired ATP turnover and ADP supply depress cardiac mitochondrial respiration and elevate superoxide in nonfailing spontaneously hypertensive rat hearts. Am J Physiol Cell Physiol 2009; 297: C766-C774.
18. Saks VA, Kaambre T, Sikk P, Eimre M, Orlova E, Paju K, Piirsoo A, Appaix F, Kay L, Regitz-Zagrosek V, Fleck E, Seppet E. Intracellular energetic units in red muscle cells. Biochem J 2001; 356: 643-657.
19. Ward M-L, Pope AJ, Loiselle DS, Cannell MB. Reduced contraction strength with increased intracellular [Ca2+] in left ventricular trabeculae from failing rat hearts. J Physiol 2003; 546: 537-550.
20. Duncan JG, Finck BN. The PPARalpha-PGC-1alpha axis controls cardiac energy metabolism in healthy and diseased myocardium. PPAR Res 2008; 2008: 253817.
21. Chen Y, Liu Y, Dorn GW II. Mitochondrial fusion is essential for organelle function and cardiac homeostasis. Circ Res 2011; 109: 1327-1331.
22. Rimbaud S, Ruiz M, Piquereau J, Mateo P, Fortin D, Veksler V, Garnier A, Ventura-Clapier R. Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PLoS ONE 2011; 6: e26391.
23. Eirin A, Williams BJ, Ebrahimi B, Zhang X, Crane JA, Lerman A, Textor SC, Lerman LO. Mitochondrial targeted peptides attenuate residual myocardial damage after reversal of experimental renovascular hypertension. J Hypertens 2014; 32: 154-165.
24. Tang Y, Mi C, Liu J, Gao F, Long J. Compromised mitochondrial remodeling in compensatory hypertrophied myocardium of spontaneously hypertensive rat. Cardiovasc Pathol 2014; 23: 101-106.
25. Walther T, Tschope C, Sterner-Kock A, Westermann D, Heringer-Walther S, Riad A, Nikolic A, Wang Y, Ebermann L, Siems WE, Bader M, Shakibaei M, Schultheiss HP, Dorner A. Accelerated mitochondrial adenosine diphosphate/adenosine triphosphate transport improves hypertension-induced heart disease. Circulation 2007; 115: 333-344.
26. Liu M, Gu L, Sulkin MS, Liu H, Jeong EM, Greener I, Xie A, Efimov IR, Dudley Jr. S.C. Mitochondrial dysfunction causing cardiac sodium channel downregulation in cardiomyopathy. J Mol Cell Cardiol 2013; 54: 25-34.
27. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 2001; 38: 1107-1111.
28. Shimizu S, Ishibashi M, Kumagai S, Wajima T, Hiroi T, Kurihara T, Ishii M, Kiuchi Y. Decreased cardiac mitochondrial tetrahydrobiopterin in a rat model of pressure overload. Int J Mol Med 2013; 31: 589-596.
29. Deng JS, Lee SD, Kuo WW, Fan MJ, Lin YM, Hu WS, Huang YC, Velmurugan BK, Tsai FJ, Tsai CH, Huang CY. Anti-Apoptotic and pro-survival effect of protocatechuic acid on hypertensive hearts. Chem Biol Interact 2014; 209: 77-84.
30. Liao XD, Wang XH, Jin HJ, Chen LY, Chen Q. Mechanical stretch induces mitochondria-dependent apoptosis in neonatal rat cardiomyocytes and G2/m accumulation in cardiac fibroblasts. Cell Res 2004; 14: 16-26.
31. Guerra S, Leri A, Wang X, Finato N, Di Loreto C, Beltrami CA, Kajstura J, Anversa P. Myocyte death in the failing human heart is gender dependent. Circ Res 1999; 85: 856-866.
32. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM, Shirani J, Armstrong RC, Kitsis RN. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003; 111: 1497-1504.
33. von Harsdorf R, Li PF, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation 1999; 99: 2934-2941.
34. Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C, Hakem R, Salvesen GS, Green DR. Catalytic activity of the caspase-8-FLIP(l) complex inhibits RIPK3-dependent necrosis. Nature 2011; 471: 363-367.
35. Wang H-J, Kang P-F, Wu W-J, Tang Y, Pan Q-Q, Ye H-W, Tang B, Li Z-H, Gao Q. Changes in cardiac mitochondrial aldehyde dehydrogenase 2 activity in relation to oxidative stress and inflammatory injury in diabetic rats. Mol Med Rep 2013; 8: 686-690.
36. Chen X-H, Zhao Y-P, Xue M, Ji C-B, Gao C-L, Zhu J-G, Qin D-N, Kou C-Z, Qin X-H, Tong M-L, Guo X-R. TNF-Alpha induces mitochondrial dysfunction in 3T3-l1 adipocytes. Mol Cell Endocrinol 2010; 328: 63-69.
37. Wenceslau CF, McCarthy CG, Szasz T, Spitler K, Goulopoulou S, Webb RC. Working Group on Di CD. Mitochondrial damage-Associated molecular patterns and vascular function. Eur Heart J 2014; 35: 1172-1177.
38. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ. Circulating mitochondrial damps cause inflammatory responses to injury. Nature 2010; 464: 104-107.
39. Shimada K, Crother TR, Karlin J, Dagvadorj J, Chiba N, Chen S, Ramanujan VK, Wolf AJ, Vergnes L, Ojcius DM, Rentsendorj A, Vargas M, Guerrero C, Wang Y, Fitzgerald KA, Underhill DM, Town T, Arditi M. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012; 36: 401-414.
40. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T, Oyabu J, Murakawa T, Nakayama H, Nishida K, Akira S, Yamamoto A, Komuro I, Otsu K. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 2012; 485: 251-255.
41. Yang Z, Gagarin D, St Laurent G III, Hammell N, Toma I, Hu C-A, Iwasa A, McCaffrey TA. Cardiovascular inflammation and lesion cell apoptosis: a novel connection via the interferon-inducible immunoproteasome. Arterioscler Thromb Vasc Biol 2009; 29: 1213-1219.
42. Kluge MA, Fetterman JL, Vita JA. Mitochondria and endothelial function. Circ Res 2013; 112: 1171-1188.
43. Luiking YC, Ten Have GA, Wolfe RR, Deutz NE. Arginine de novo and nitric oxide production in disease states. Am J Physiol Endocrinol Metab 2012; 303: E1177-E1189.
44. Wang XP, Zhang W, Liu XQ, Wang WK, Yan F, Dong WQ, Zhang Y, Zhang MX. Arginase i enhances atherosclerotic plaque stabilization by inhibiting inflammation and promoting smooth muscle cell proliferation. Eur Heart J 2014; 35: 911-919.
45. Hoang HH, Padgham SV, Meininger CJ. L-Arginine, tetrahydrobiopterin, nitric oxide and diabetes. Curr Opin Clin Nutr Metab Care 2013; 16: 76-82.
46. Michell DL, Andrews KL, Chin-Dusting JP. Endothelial dysfunction in hypertension: The role of arginase. Front Biosci (Schol Ed) 2011; 3: 946-960.
47. Kizhakekuttu TJ, Wang J, Dharmashankar K, Ying R, Gutterman DD, Vita JA, Widlansky ME. Adverse alterations in mitochondrial function contribute to type 2 diabetes mellitus-related endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2012; 32: 2531-2539.
48. Riehle C, Wende AR, Zaha VG, Pires KM, Wayment B, Olsen C, Bugger H, Buchanan J, Wang X, Moreira AB, Doenst T, Medina-Gomez G, Litwin SE, Lelliott CJ, Vidal-Puig A, Abel ED. PGC-1beta deficiency accelerates the transition to heart failure in pressure overload hypertrophy. Circ Res 2011; 109: 783-793.
49. Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, PriceJWIII, Kang L, Rabinovitch PS, Szeto HH, Houmard JA, Cortright RN, Wasserman DH, Neufer PD. MitochondrialH2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 2009; 119: 573-581.
50. Puigserver P, Spiegelman BM. Peroxisome proliferator-Activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003; 24: 78-90.
51. Chaanine AH, Gordon RE, Kohlbrenner E, Benard L, Jeong D, Hajjar RJ. Potential role of BNIP3 in cardiac remodeling, myocardial stiffness, and endoplasmic reticulum: mitochondrial calcium homeostasis in diastolic and systolic heart failure. Circ Heart Fail 2013; 6: 572-583.
52. Valnot I, Kassis J, Chretien D, de Lonlay P, Parfait B, Munnich A, Kachaner J, Rustin P, Rotig A. A mitochondrial cytochrome b mutation but no mutations of nuclearly encoded subunits in ubiquinol cytochrome c reductase (complex III) deficiency. Hum Genet 1999; 104: 460-466.
53. Wilson FH, Hariri A, Farhi A, Zhao H, Petersen KF, Toka HR, Nelson-Williams C, Raja KM, Kashgarian M, Shulman GI, Scheinman SJ, Lifton RP. A cluster of metabolic defects caused by mutation in a mitochondrial t RNA. Science 2004; 306: 1190-1194.
54. Zhou L, Wang DF, Zhang GY, Li HN, Zhang PP, Zhao XT, Gu JR, Liew CC. Cloning, expression andmutation of mitochondrialATPase gene of hypertensive patients and rats. ACTA 1999; 21: 729-732.
55. Schmitt R, Melk A. New insights on molecular mechanisms of renal aging. Am J Transplant 2012; 12: 2892-2900.
56. Jin K, Vaziri ND. Salt-sensitive hypertension in mitochondrial superoxide dismutase deficiency is associated with intra-renal oxidative stress and inflammation. Clin Exp Nephrol 2013; 18: 445-452.
57. de Cavanagh EM, Toblli JE, Ferder L, Piotrkowski B, Stella I, Inserra F. Renal mitochondrial dysfunction in spontaneously hypertensive rats is attenuated by losartan but not by amlodipine. Am J Physiol Regul Integr Comp Physiol 2006; 290: R1616-R1625.
58. Zheleznova NN, Yang C, Ryan RP, Halligan BD, Liang M, Greene AS, Cowley AWJr. Mitochondrial proteomic analysis reveals deficiencies in oxygen utilization in medullary thick ascending limb ofHenle in the Dahl salt-sensitive rat. Physiol Genomics 2012; 44: 829-842.
59. Boveris A, Valdez LB, Zaobornyj T, Bustamante J. Mitochondrial metabolic states regulate nitric oxide and hydrogen peroxide diffusion to the cytosol. Biochim Biophys Acta 2006; 1757: 535-542.
60. Eirin A, Li Z, Zhang X, Krier JD, Woollard JR, Zhu XY, Tang H, Herrmann SM, Lerman A, Textor SC, Lerman LO. A mitochondrial permeability transition pore inhibitor improves renal outcomes after revascularization in experimental atherosclerotic renal artery stenosis. Hypertension 2012; 60: 1242-1249.
61. Fedorova LV, Sodhi K, Gatto-Weis C, Puri N, Hinds TD Jr, Shapiro JI, Malhotra D. Peroxisome proliferator-Activated receptor delta agonist, HPP593, prevents renal necrosis under chronic ischemia. PLoS ONE 2013; 8: e64436.
62. Sumbalova Z, Kucharska J, Kristek F. Losartan improved respiratory function and coenzyme Q content in brain mitochondria of young spontaneously hypertensive rats. Cell Mol Neurobiol 2010; 30: 751-758.
63. Doroshchuk AD, Postnov A, Afanaseva GV, Budnikov E, PostnovIu V. [Decreased ATP-synthesis ability of brain mitochondria in spontaneously hypertensive rats]. Kardiologiia 2004; 44: 64-65.
64. Lopez-Campistrous A, Hao L, Xiang W, Ton D, Semchuk P, Sander J, Ellison MJ, Fernandez-Patron C. Mitochondrial dysfunction in the hypertensive rat brain: respiratory complexes exhibit assembly defects in hypertension. Hypertension 2008; 51: 412-419.
65. Costa LE, La-Padula P, Lores-Arnaiz S, DAmico G, Boveris A, Kurnjek ML, Basso N. Long-Term angiotensin ii inhibition increases mitochondrial nitric oxide synthase and not antioxidant enzyme activities in rat heart. J Hypertens 2002; 20: 2487-2494.
66. Kanai A, Epperly M, Pearce L, Birder L, Zeidel M, Meyers S, Greenberger J, de Groat W, Apodaca G, Peterson J. Differing roles of mitochondrial nitric oxide synthase in cardiomyocytes and urothelial cells. Am J Physiol Heart Circ Physiol 2004; 286: H13-H21.
67. Piotrkowski B, Koch OR, De Cavanagh EM, Fraga CG. Cardiac mitochondrial function and tissue remodelling are improved by a non-Antihypertensive dose of enalapril in spontaneously hypertensive rats. Free Radic Res 2009; 43: 390-399.
68. Zhang X, Li ZL, Crane JA, Jordan KL, Pawar AS, Textor SC, Lerman A, Lerman LO. Valsartan regulates myocardial autophagy and mitochondrial turnover in experimental hypertension. Hypertension 2014; 64: 87-93.
69. Piotrkowski B, Fraga CG, de Cavanagh EM. Mitochondrial function and nitric oxide metabolism are modified by enalapril treatment in rat kidney.Am J Physiol Regul Integr Comp Physiol 2007; 292: R1494-R1501.
70. Abadir PM, Foster DB, Crow M, Cooke CA, Rucker JJ, Jain A, Smith BJ, Burks TN, Cohn RD, Fedarko NS, Carey RM, ORourke B, Walston JD. Identification and characterization of a functional mitochondrial angiotensin system. Proc Natl Acad Sci USA 2011; 108: 14849-14854.
71. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin ii-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 2008; 102: 488-496.
72. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin ii stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
73. de Cavanagh EM, Inserra F, Ferder L, Romano L, Ercole L, Fraga CG. Superoxide dismutase and glutathione peroxidase activities are increased by enalapril and captopril in mouse liver. FEBS Lett 1995; 361: 22-24.
74. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, Murphy MP. Selective targeting of a redox-Active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 2001; 276: 4588-4596.
75. Graham D, Huynh NN, Hamilton CA, Beattie E, Smith RA, Cocheme HM, Murphy MP, Dominiczak AF. Mitochondria-Targeted antioxidant mitoq10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 2009; 54: 322-328.
76. McLachlan J, Beattie E, Murphy MP, Koh-Tan CH, Olson E, Beattie W, Dominiczak AF, Nicklin SA, Graham D. Combined therapeutic benefit of mitochondria-Targeted antioxidant, Mitoq10, and angiotensin receptor blocker, losartan, on cardiovascular function. J Hypertens 2014; 32: 555-564.
77. Singh D, Chander V, Chopra K. Cyclosporine protects against ischemia/reperfusion injury in rat kidneys. Toxicology 2005; 207: 339-347.
78. Bloom IT, Bentley FR, Garrison RN. Acute cyclosporine-induced renal vasoconstriction is mediated by endothelin-1. Surgery 1993; 114: 480-487; discussion 487-488.
79. Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf 1999; 20: 437-449.
80. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol 2014; 171: 2029-2050.
81. Dai D-F, Chen T, Szeto H, Nieves-Cintron M, Kutyavin V, Santana LF, Rabinovitch PS. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol 2011; 58: 73-82.
82. Eirin A, Ebrahimi B, Zhang X, Zhu XY, Woollard JR, He Q, Textor SC, Lerman A, Lerman LO. Mitochondrial protection restores renal function in swine atherosclerotic renovascular disease. Cardiovasc Res 2014; 103: 461-472.
83. Smith RAJ, Murphy MP. Animal and human studies with the mitochondria-Targeted antioxidant mitoq. Ann N Y Acad Sci 2010; 1201: 96-103.
84. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, Andre-Fouet X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359: 473-481.
85. Chakrabarti AK, Feeney K, Abueg C, Brown DA, Czyz E, Tendera M, Janosi A, Giugliano RP, Kloner RA, Weaver WD, Bode C, Godlewski J, Merkely B, Gibson CM. Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for st-segment elevation myocardial infarction. Am Heart J 2013; 165: 509-514.e507.
86. Dikalov SI, Nazarewicz RR, Bikineyeva A, Hilenski L, Lassegue B, Griendling KK, Harrison DG, Dikalova AE. Nox2-induced production of mitochondrial superoxide in angiotensin II-mediated endothelial oxidative stress and hypertension. Antioxid Redox Signal 2014; 20: 281-294.